

Therapeutic application of natural inhibitors against snake venom phospholipase A₂

Ramar Perumal Samy^{1,2,*}, Ponnampalam Gopalakrishnakone², Vincent TK Chow¹

¹Infectious Disease Programme, Department of Microbiology; ²Venom and Toxin Research Programme, Department of Anatomy; Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597; Ramar Perumal Samy-Email: micramar@nus.edu.sg; Phone: +65 - 65163207, Fax: +65- 67787643; *Corresponding author

Received December 14, 2011; Accepted December 17, 2011; Published 06, 2012

Abstract:

Natural inhibitors occupy an important place in the potential to neutralize the toxic effects caused by snake venom proteins and enzymes. It has been well recognized for several years that animal sera, some of the plant and marine extracts are the most potent in neutralizing snake venom phospholipase A₂ (svPLA₂). The implication of this review to update the latest research work which has been accomplished with svPLA₂ inhibitors from various natural sources like animal, marine organisms presents a compilation of research in this field over the past decade and revisiting the previous research report including those found in plants. In addition to that the bioactive compounds/inhibitor molecules from diverse sources like aristolochic alkaloid, flavonoids and neoflavonoids from plants, hydrocarbons -2, 4 dimethyl hexane, 2 methylnonane, and 2, 6 dimethyl heptane obtained from traditional medicinal plants *Tragia involucrata* (Euphorbiaceae) member of natural products involved for the inhibitory potential of phospholipase A₂ (PLA₂) enzymes *in vitro* and also decrease both oedema induced by snake venom as well as human synovial fluid PLA₂. Besides marine natural products that inhibit PLA₂ are monoalide and its derivatives such as scalaradial and related compounds, pseudopterosins and vidalols, tetracycline from synthetic chemicals etc. There is an overview of the role of PLA₂ in inflammation that provides a rationale for seeking inhibitors of PLA₂ as anti-inflammatory agents. However, more studies should be considered to evaluate antivenom efficiency of sera and other agents against a variety of snake venoms found in various parts of the world. The implications of these new groups of svPLA₂ toxin inhibitors in the context of our current understanding of snake biology as well as in the development of new novel antivenoms therapeutics agents in the efficient treatment of snake envenomations are discussed.

Keywords: Inhibitors, Phospholipase A₂, Snake venom phospholipase A₂, Envenomation, Inflammation

Background:

Snake envenomation is a serious medical problem, especially in the farms where snakes are abundant [1]. The common species such as *Crotalus rhodostoma* (38%), *Trimeresurus albolabris* (27%), *Daboia russeli siamensis* (14%), *Naja atra* (10%), and others (11%) are responsible for snakebites in Southeast Asia [2]. Snake venoms constitute a rich source of phospholipase A₂ (PLA₂) enzymes, which show remarkable functional diversity. Snake venom phospholipase A₂ (svPLA₂) can induce several additional effects such as cardiotoxicity, myotoxicity, pre or postsynaptic neurotoxicity, edema, hemolysis, hypotension, convulsion, platelet aggregation inhibition and anticoagulation

[3-5]. svPLA₂ catalyze the hydrolysis of 2-acyl ester bonds of 3-sn-phospholipids producing fatty acids and lysophospholipids [6]. The Ca²⁺ ion, an essential cofactor, and an Asp residue at position 49 are required for catalysis on artificial substrates [6]. Their catalytic activity upon cell membranes of specific tissues suggests an important role of these enzymes in venoms toxicity.

PLA₂s were recently divided into 15 groups based on biochemical and structural criteria, considering their molecular weight, disulfide bonds profile, phospholipid substrates, amino acid sequence, and sensibility to Ca²⁺ ions, catalytic activity and genic structure [7-9]. Snake venoms are especially rich in

group I and II PLA₂s, found in the Elapidae or Viperidae families, respectively. Group II PLA₂s can be further subdivided into two main types commonly referred to as Asp-49 and Lys-49 isoforms [10]. Since then, the isoforms of basic myotoxic PLA₂s were isolated from *Bothrops* snakes and classified into group II, where the Asp-49 residue was replaced by Lys-49, resulting thus two classes of this enzyme: (a) Asp-49 myotoxins showing moderate catalytic activity and (b) Lys-49 myotoxins with low or no enzymatic activity upon artificial substrates [9-10]. Previously, myonecrotic venom components were extensively studied. Several myotoxic *Bothrops* PLA₂s were characterized, such as *B. asper* PLA₂s, *B. moojeni* myotoxins I and II, and *B. jararacussu bothropstoxins* I (Lys-49) and II (Asp-49), responsible for several biological effects including myonecrosis, edema, irreversible neuromuscular blockage and *in vitro* cell lysis [11-14] etc. Many acidic PLA₂s have been isolated from *Agkistrodon halys*, *Pseudechis papuanus*, *Bothrops neuwiedi*, *Bothrops lanceolatus*, *Trimeresurus jerdonii*, *Heloderma horridum*, *Ophiophagus hannah*, *Lachesis muta*, *B. jararaca*, *B. moojeni* and *B. jararacussu* [15-19]. Toxicity and pharmacological effects differ in acidic isoforms. For example, the acidic PLA₂ isolated from *Lachesis muta* venom is myonecrotic, proteolytic, anticoagulant and platelet aggregation inhibitor. Another myotoxic PLA₂ from the same venom did not show anticoagulant or lethal activity.

It has been suggested that PLA₂s represent a class of versatile enzymes and, as multifunctional proteins; they are extremely relevant as mediators of several inflammatory diseases and promising agents for use in biotechnological areas [20-21]. An increasing search for use of these enzymes is therefore not surprising, including their general anesthetic action, treatment of rheumatoid arthritis, bactericidal action, novel class of antiparasitary agents, HIV inhibitors and others [22-26]. In this review, we broadly discuss the implications of the PLA₂ inhibitor groups of plants, marine organisms serve as sources of compounds on current understanding of snake biology, as well as in the development of new therapeutic drugs for treatment of snake envenomations.

Venom neutralization by bio-active compounds from plant:

a) Neutralization potential of crude mixture of plants

Many plants are used in traditional medicine as active agents against various effects induced by snakebite [27]. Viperidae snakes (*Daboia russelli russelli*) are well known for severe local effects and these effects commonly treated with plant extracts without any scientific validation in triabl areas, India [28]. There are few survey reports that reveal the practice of herbal medicine by either folk or indigenous communities [29-31]. However, in most cases the efficacy of this traditional treatment regimen is unproven. Thus, the study of herbal antidotes against snake venom is of great importance in the management of snakebite. Recently, various research groups actively engaged for antivenom research by using diversified crude extracts and elucidated active compounds from various plants sources [27, 32-34]. In addition, their natural PLA₂ inhibitors also play an important role in some traditional medicines used for immune support, such as the ashwaganda plant (*Withania somnifera*) used in Ayurvedic medicine. Aqueous extracts of this plant have been reported to neutralize venom of the Indian speckled cobra -*Naja naja* [35] Another report, ethanolic seed extract of *Strychnos nux-vomica* also showed antisnake venom activity [36]. Ethanolic leaf extract of *Acalypha indica* potentially

neutralized *Viper russelli russelli* (Russell's viper) venom [37]. *Morus alba* leaf extract abolished the *in vitro* proteolytic and hyaluronolytic activities of Indian viper *Daboia russelli* venom. Edema, hemorrhage and myonecrotic activities were also neutralized effectively [28]. Aqueous root extract of *Mimosa pudica* inhibited the hyaluronidase and protease activities of Indian snake (*Naja naja*, *Vipera russelli* and *Echis carinatus*) venoms by dose dependant manner [38].

The ethanol leaf extract and essential oil of *Nectandra angustifolia* was the most active and inhibited both venom activities (hemolytic and coagulant), while the oil was only active on the coagulant activity [39]. Methanol extract of fresh leaves (*Camellina sinensis* L.) showed potential to inhibit PLA₂ enzymes with hydrolytic activity in *Naja naja kaouthia* Lesson and *Calloselasma rhodostoma* Kuhl venoms [40]. Another, methanolic extract from *Cordia verbenacea* 'baleira', 'whaler' (Cv) significantly inhibited paw edema induced by *Bothrops jararacussu* snake venom and by its main basic phospholipase A₂ homologs, namely bothropstoxins I and II (BthTXs). Alam et al, [41] also reported that the isolation, purification and partial characterization of viper venom inhibiting factor from the root extract of the Indian medicinal plant sarsaparilla (*Hemidesmus indicus* R.Br.). Viper venom-induced inflammation and inhibition of free radical formation by pure compound (2-hydroxy-4-methoxy benzoic acid) isolated and purified from anantamul (*Hemidesmus indicus* R.Br.) root extract [42].

In our previous study, the herbal practitioners in the study area were interviewed, and information on medicinal plants was collected from the traditional healers called "Vaidyars". This survey covers 72 medicinal plants belonging to 53 families that are used for the treatment of snakebite in a traditional way. Traditional approach was evaluated scientifically with some selected plant extracts (7.2 mg/kg, body weight) and partially purified fractions (2.4 mg/kg, b.w) were orally administered to mice experimentally envenomed with rattlesnake venom s.c. injection (2.5 - 15 mg/kg, b.w). Tested fractions (*Aristolochia indica*, *Hemidesmus indicus*, *Gloriosa superba*, *Strychnos nux-vomica*, *Eclipta prostrata*, and *Andrographis paniculata*) showed potent neutralizing effect against the venom. Compared to the extracts, administration of purified fractions was more effective in increasing the body weight. Control mice injected with the venom alone showed weight loss and severe toxicity at 15 mg/kg, b.w. The purified fractions (2.4 mg/kg, b.w) produced significant protection against venom induced changes in serum SOD and LPx levels. The isolated fractions effectively inhibited the toxic effect of snake venoms *in vitro* than *in vivo*. The above observations confirmed the protective activity of plants - *Aristolochia indica*, *Hemidesmus indicus*, *Gloriosa superba*, *Strychnos nux-vomica*, *Eclipta prostrata*, and *Andrographis paniculata* against the lethal action of snake venom [33].

Several plants are used in traditional medicine as active agents against various effects induced by snakebite [27, 32]. Folk medicine and its isolated constituents recommended as snake venom antidotes for the protection against *Jararaca* venom [43] for i.e. haemorrhagic effect of *Bothrops atrox* venom and their strong lethal enzymatic effect was neutralized by plants [44-45]. Furthermore, previously we reported [33] hydrocarbones such as 2, 4 dimethyl hexane, 2 methylnonane, 2, 6 dimethyl heptane obtained from traditional medicinal plants *Tragia involucrata*

(Euphorbiaceae) member showed effective venom and PLA₂ neutralisation in mice (Figure 1A). PLA₂ inhibitors have also been isolated from plants such as *Horsfieldia amygdaline* [46].




Figure 1: Structure of various bioactive molecules involved for the inhibitory potential of phospholipase A₂ (PLA₂) enzymes *in vitro* and also decrease both oedema induced by snake venom as well as human synovial fluid PLA₂. (A) Hydrocarbons like 2, 4 dimethyl hexane, 2 methylnonane, 2,6 dimethyl heptane obtained from traditional medicine plants *Tragia involucrate* (Euphorbiaceae) member (Samy *et al*, *J Ethnopharmacol*. 2006,107(1):99-106), (B) Aristolochic alkaloid, (C) Flavonoids and neoflavonoids from plants (D) Manolide and scalaradial from marine sources (E) tetracycline (antibiotics)

The active component was isolated and identified as rosmarinic acid (RA). RA is an ester of caffeic acid and 3, 4-dihydroxyphenyllactic acid [2-O-caffeoyl-3-(3, 4-dihydroxyphenyl)-L-lactic acid [32]. RA in the species *C. verbenacea* and of its anti-inflammatory and antimyotoxic properties against snake venoms and isolated toxins reported for the first-time. RA inhibited the edema and myotoxic activity induced by the basic PLA₂s BthTX-I and BthTX-II. The pure compound potentiated the ability of the commercial equine polyvalent antivenom in neutralizing lethal and myotoxic effects of the crude venom as well as isolated PLA₂s in experimental models. Circular dichroism data also suggested that after binding, no significant conformation changes were occurred either in the Cv-RA or in the target PLA₂. A possible model for the interaction of RA with Lys49-PLA₂ BthTX-I is proposed [32]. A compound AIPLAI purified from the methanolic leaf extract of *Azadirachta indica* (Neem) inhibits the *Cobra* and Russell's viper venoms (RVVs) PLA₂ enzymes in a dose-dependent manner and the AIPLAI holds good promise for the development of novel anti-snake venom drug in future [34].

The secondary metabolites (chemical constituents) are responsible for the neutralizing effect of plants that are in popular use against the action of snake venoms [47-48]. An animal study has also been well documented in the case of immunity of the opossum (*Didelphis marsupials*) towards the venom of the *Jararaca* (*Bothrops jararaca*) snake [49]. Plants are reputed to be capable of neutralizing the action of snake venom, and their antivenom activity has been related to certain chemical compounds identified in those plants [43]. Several chemical constituents like alkaloids, flavonoids, sitosterol or glucoside, lupeol, gymnemagenin, phenolics, pentacyclic triterpenes like oleanolic acid, ursolic, tannins, taraxasterol, α and β amyryn are found to be present in varying proportions in plants. They have also been previously reported for antivenom activity. All these classes of chemical compounds are capable of interacting with macromolecular targets with enzymes or receptors and it can effectively inhibit the toxic effect of snake venoms *in vitro* than *in vivo* [50]. Besides, several other phytochemicals of plant origin showed the most potent inhibition of human synovial fluid phospholipase (HSF- PLA₂) was observed with compounds such as scalaradial and ellagic acid, which both have IC₅₀ values of 0.02 μ M (using autoclaved [3H]-arachidonic-acid (AA)-labelled *Escherichia coli* membranes as substrate).

b) Alkaloids

Recently, alkaloid has been reported that aristolochic acid inhibits PLA₂ *in vitro* and also decrease both oedema induced by snake venom as well as human synovial fluid PLA₂ (Figure 1B). Several authors studied the anti-inflammatory activity of aristolochic acid and to investigate the effect of the alkaloid on the enzymes involved in the release of eicosanoids. Results demonstrated that aristolochic acid was inhibited the inflammation induced by immunological, immune complexes, and non-immunological agents such as carrageenan or croton oil [51].

c) Flavonoids

The inhibitory effect of the plant flavonoid and rutin were investigated against group I PLA₂ from porcine pancreas and *Naja naja* as well as group II PLA₂s from *Vipera russelli* and *Crotalus atrox* etc (Figure 1C). Rutin efficiently inhibited group II PLA₂s obtained both *V. russelli* and *C. atrox* but it was shown only a weak inhibitor of PLA₂-I from porcine pancreas and *N. naja*. The lack of strong inhibition of pancreatic PLA₂-I was not due to contaminating proteins in the enzyme preparation, since the same weak inhibition was obtained against pancreatic PLA₂ purified to homogeneity as well [52]. The phytotherapeutic agent like flavonoids selectively inhibited the group II PLA₂ of venom origins. Previously, Alcaraz and Hoult [53] reported that the hypolaetin-8-glucoside and related flavonoids inhibited the snake venom phospholipase A₂ effectively. Porcine pancreatic PLA₂ hydrolyses phosphatidylcholine when in the lamellar state as well as in the micellar state. We have found that alpha-tocopherol, the most active form of vitamin E, is able to inhibit PLA₂ activity only toward lamellar fluid membranes, thus protecting phospholipids toward this lytic enzyme. This compound decreases both the initial rate and the extent of hydrolysis. The inhibition is of the non-competitive type and the evidence strongly suggests that it is mainly due to an effect of alpha-tocopherol on the substrate, i.e. the membrane and not, on the enzyme [54].

d) Lipids

Membrane lipid-derived second messengers are generated by PLA₂ during synaptic activity. Overstimulation of this enzyme during neurotrauma results in the accumulation of bioactive metabolites such as arachidonic acid, oxygenated derivatives of arachidonic acid, and platelet-activating factor (PAF). Several of these bioactive lipids participate in cell damage, cell death, or repair-regenerative neural plasticity. Neurotransmitters may activate PLA₂ directly when linked to receptors coupled to G proteins and/or indirectly as calcium influx or mobilization from intracellular [55]. Chronic inflammatory diseases are often accompanied by intense angiogenesis. A model of inflammatory angiogenesis is the murine air pouch granuloma which has a hyperangiogenic component. Proinflammatory lipid mediator generation is also a hallmark of chronic inflammation and the role of endogenous production of these mediators in angiogenesis is not known. The 14 kDa PLA₂ deacylates phospholipid, liberating arachidonic acids are used for leukotriene and lysophospholipid, production of platelet-activating factor (PAF) [56]. Another report, 1-alkyl ether lipids were studied for their ability to inhibit PLA₂ and antagonize PAF responses. Studies with synthetic micellar substrate (1-stearyl-2-arachidonyl phosphocholine), at concentrations ranging from 0.02 to 1000 μM, demonstrate that CL 118326 inhibits porcine pancreatic PLA₂ *in vitro*. As the substrate concentration increases, there is a dose-dependent increase in the IC₅₀ value (IC₅₀ ranges: 2.6-137 μM). CL 118326 inhibits mammalian pancreatic PLA₂, but not snake or bee venom PLA₂. CL 118326 inhibits thrombin effectively at IC₅₀ = 7.9 μM dose [57].

Phospholipase A₂ (PLA₂) inhibitors from marine organisms:

Phospholipase A₂ (PLA₂) inhibitor from marine organisms that are provides a rationale for seeking inhibitors of PLA₂ as anti-inflammatory agents [58]. Marine natural products that inhibit PLA₂ are manoalide [59-63] and its derivatives such as scalaradial [64] and related compounds like pseudopterosins [65], vidalols, and a group of terpenoids that contain masked 1,4-dicarbonyl moieties respectively.

a) Manoalide

Several marine terpenoids that contain at least one reactive aldehyde group, such as manoalide (MLD) and its congeners, possess interesting anti-inflammatory activities that are mediated by the covalent inactivation of secretory phospholipase A₂ [63]. Manoalide is a potent analgesic and anti-inflammatory sesterterpene isolated in 1980 from a marine sponge. The anti-inflammatory activity of manoalide is due to inhibition of PLA₂, through irreversible binding to several lysine residues (Figure 1D). This binding is realized by means of the two masked aldehyde functions present in the polar part of manoalide. Of the two aldehyde groups, only that present in the g-hydroxybutenolide ring seems to be essential, since cacospongionolides, naturally occurring analogues lacking the second masked aldehyde group, were also shown to be irreversible PLA₂ inhibitors. It appears that the minimum structural requirement for exhibiting manoalide-like PLA₂ inhibition would be the presence in the inhibitor of functional groups able to seize the amino groups of PLA₂ lysine residues with formation of stable covalent bonds. Many manoalide analogues have been isolated from marine sponges, most of them sharing PLA₂ inhibitory properties [62].

MLD inactivated bee venom phospholipase A₂s, localization of the manoalide binding site on bee venom PLA₂ [59-60]. MLD drug inhibited purified human synovial fluid phospholipase A₂ (HSF-PLA₂). Inhibition of HSF-PLA₂ by MLD was concentration and time dependent with IC₅₀ values of 0.2 and 0.02 μM for dipalmitoylphosphatidylcholine (DPPC) as the substrate (38.0 μM and 18.8 μmol) [3H]arachidonic acid released/min/mg protein with *Escherichia coli* as a natural substrate respectively [61].

b) Scalaradial

Scalaradial (SLD), a 1, 4-dialdehyde marine terpenoid that was isolated from the sponge (*Cacospongia mollior*) possesses anti-inflammatory properties *in vivo* and *in vitro*. SLD is a potent inactivator of bee venom PLA₂ with an IC₅₀ value of 0.07 μM. Inactivation of bee venom PLA₂ occurred in a time-dependent manner. The rate of inactivation was reduced markedly in the presence of excess phosphatidylcholine, suggesting that modification of the enzyme occurs at or near the substrate binding site [64]. Due to its peculiar dialdehyde structural feature, it has been proposed that scalaradial exerts its enzymatic inactivation by means of an irreversible covalent modification of its target [63].

c) Petrosaspongiolide

Petrosaspongiolide M (PM) is an anti-inflammatory marine metabolite that displays a potent inhibitory activity toward group II and III secretory phospholipase A₂ (PLA₂) enzymes. The details of the mechanism, which leads to a covalent adduct between PLA₂ and gamma-hydroxybutenolide-containing molecules such as PM. The model provides an interesting insight into the PM-PLA₂ inhibition process and may prove useful in the design of new anti-inflammatory agents that target PLA₂ secretory enzymes [65].

d) Vidalols

Chemical studies of the Caribbean red alga *Vidalia obtusiloba* have resulted in the isolation of two new bromophenolic metabolites, vidalols A and B (1, 2). The new compounds were discovered as part of an organized effort to isolate new naturally-occurring anti-inflammatory agents with a focus upon those which may function through the inhibition of PLA₂ [66]. A chemically synthesized novel phenolic metabolite, vidalenolone, as well as two previously described and structurally simple phenols were isolated as SH₂-inactive substances. Their structures were determined by spectroscopic methods such as 2D NMR [67]. The cytotoxic activities of all the synthetic compounds were determined against DLD-1 cells using the MTT assay. Compounds with IC₅₀ < 20 μmol were also tested against HCT-116 cells. Compound 3c (2, 5-dibromo-3, 4-dihydroxybenzyl n-propyl ether) was the most active compound against both cell lines (IC₅₀ = 1.72 and 0.80 μmol, respectively), and its effect on the cell cycle was studied using flow cytometry [68].

Other lead molecules as PLA₂ inhibitors:

Analogues of lead molecules were generated by substituting different types of functional groups in order to obtain a molecule with optimal PLA₂ inhibition. The lead molecules characterized as PLA₂ inhibitors are acenaphthenes, azetidinones, indoles, piperazines, isoxazolidines, isoxazolines, diazepinones, and several substrate analogues [69]. Among

these analogue piperazine derivatives on optimization with respect to hydrophobicity and electronegativity showed inhibition at nanomolar levels. Structural analysis of many lead molecules indicated that a PLA₂ inhibitor should have both hydrophobic moiety and polar functional groups. However, the docking studies clearly showed that the binding mechanisms of plant (acalyphin, chlorogenic acid, stigmaterol, curcumin and tectoridin) and marine compounds (gracilin A and aplysulphurin A), performed with Russell's viper and bovine pancreatic PLA₂ as target molecules. These compounds interacted with the amino acid (AA) residues at the active site of both PLA₂s, and proved the efficacy as anti-inflammation and as well antidotes properties [70].

Antibiotic as a PLA₂ inhibitor

a) Tetracyclines as PLA₂ inhibitor

Tetracyclines are primarily bacteriostatic broad-spectrum antimicrobial agents; they are thought to exert their effect by the inhibiting protein synthesis. Tetracyclines at low doses were found to interfere with the production of prostaglandins and leukotrienes [71-72], scavenge oxygen radicals [73], interfere with the expression of nitrous oxide synthase [74], and enhance natural inhibitors of matrix metalloproteinases [75-76] after this novel discovery non-antimicrobial chemically modified tetracyclines (CMT) were prepared and widely investigated in different type of diseases (Figure 1E).

Tetracyclines have been recognized as useful agents for therapy of inflammatory arthritis [77], non-infected corneal ulcers, serious (sometimes life-threatening) skin-blistering diseases, rheumatoid arthritis and osteoarthritis, systemically as well as locally induced bone loss, suppress connective tissue breakdown during periodontal disease and perhaps even tumor-induced angiogenesis [78-80]. However, prolonged use of tetracyclines is limited by their detrimental antimicrobial properties. Recently, a group of chemically modified tetracyclines CMT, CMT-3 and CMT-5 [81] devoid of antimicrobial properties has been synthesized. However, the CMT-3 (COL-3) is produced by deletion of the dimethylamino group from carbon 4 in the A ring of tetracycline, which abolishes the antibiotic activity but not the anti-MMP activity of the molecule. Further modification by replacement of the carbon 11 carbonyl oxygen and the carbon 12 hydroxyl groups with nitrogen, abolishes the anti-MMP activity, giving rise to CMT-5 (COL-5), which is neither antibiotic nor anti-MMP [79]. Some CMT were found to inhibit various matrix-metalloproteinase (MMPs) [79, 82, 83]. Nearly 10 synthetic CMT were tested for inhibition of sPLA₂ human porcine PLA₂, and *Naja naja* PLA₂. PLA₂ activity was assessed by radio labeled *Escherichia coli* assay using standard and high calcium concentrations. Of which 6 CMT inhibited sPLA₂ activity at 50 µg/ml or lower concentrations [77]. However, the other antibiotics such as tetracyclines, macrolides, chloramphenicol and carbenicillin inhibited the activity of *Crotalus adamanteus* PLA₂ towards phospholipids of egg-yolk emulsions [84]. For example, an assessment of metalloproteinase inhibitors clodronate and doxycycline showed effective neutralization of hemorrhage and coagulopathy induced by *Bothrops asper* snake venom [85].

Tetracyclines also inhibit cell proliferation, cell migration, and synthesis of the extracellular matrix in a variety of cell types

studied in culture [86]. However, the earlier studies have shown that CMT-3 and CMT-8 inhibit tumor metastasis and arthritis-affected synoviocyte invasion in animal models [87]. In addition, doxycycline, CMT-1, and CMT-8 exerted a direct dose-dependent inhibition of porcine periodontal ligament epithelial cell medium MMP activity as assayed by gelatin enzymography. Both the 92-kDa (MMP-9) and 72-kDa (MMP-2) gelatinases were inhibited by the tetracyclines added to the conditioned medium. Culturing the cells in the presence of the tetracyclines required considerably smaller concentrations to reduce the secreted MMP activity. The drugs were not toxic to the epithelial cells at 4 to 250 µg/ml concentrations up to 24 h of culture. Doxycycline and the chemically modified tetracyclines, in addition to inhibiting the MMP activity may also reduce the enzyme expression at the transcriptional level [88]. Doxycycline and 4-de-dimethylaminotetracycline (CMT-1) have been tested *in vitro* for their ability to inhibit human neutrophil and fibroblast interstitial collagenases and collagenase in human gingival crevicular fluid (GCF). Human fibroblast collagenase and GCF collagenase from LJP patients were both relatively resistant to tetracycline inhibition; the IC₅₀ for doxycycline and CMT-1 for these 2 sources of collagenase were 280 and 500 µM, respectively [89-90]. The presence of 25 µM CMT-3, the 48/80-induced histamine release from rat serosal mast cells was inhibited significantly, to 43.0 ± 7.3% of control. Similarly, the activation-induced secretion of TNF-α and IL-8 by HMC-1 cells were decreased in the presence of 25 µM CMT-3 to 13.5 ± 4.1% and 9.7 ± 1.1% of control, respectively [91]. Adding CMT-3 at final concentrations of 5 - 20 µM inhibited MT1-MMP gelatinolytic and caseinolytic activity, blocked MT1-MMP activation of pro-MMP-2, and decreased invasiveness (using the Matrigel system) of HT-1080 fibrosarcoma cells [92]. Six different CMT to inhibit human and chicken MMP were studied *in vitro*. The ability of tetracycline and its analogs to inhibit MMP appears to depend on the Ca⁺⁺/Zn⁺⁺ binding site at C11 (carbonyl oxygen) and C12 (OH group) of the molecule, which is lacking in CMT-5, the pyrazole derivative of tetracycline [93].

b) Lipophilic tetracyclines such as minocycline and doxycycline

Previous study reported that the doxycycline, minocycline [74], and chemically modified tetracyclines (CMTs) [94] inhibit inducible NO synthase (iNOS) expression in murine macrophages. Tilley and colleagues [95], reported that the tetracyclines, particularly minocycline and doxycycline, are potent inhibitors of collagenases and gelatinases, two matrix metalloproteinases [96, 97] showed a significant reduction of the collagenolytic activity of synovial tissue obtained from six patients with rheumatoid arthritis who received minocycline before total joint arthroplasties compared with the collagenolytic activity of synovium obtained from the same patients during a previous arthroplasty when they had not received minocycline. Minocycline and doxycycline also inhibit PLA₂ *in vitro* [77, 98], another mediator of inflammation [99]. Tetracycline has also been reported to decrease leukotaxis and to inhibit phagocytosis by neutrophils, lymphocyte proliferative responses, and anti-CD3-induced synovial T-cell proliferation in a dose-dependent manner [79, 100]. Some of these anti-inflammatory properties have been shown in a chemically modified tetracycline analog that has no antibacterial effects [79,101,102]. Recently, several *in vitro* and fewer *in vivo* studies have shown that tetracyclines, non-antibacterial, non-chelating hydroxypyrazoline derivative of minocycline, 12 S-hydroxy-1,

12-pyrazolinomycinocycline (PMIN), also induced antinociceptive and anti-inflammatory effects in rats [103].

Cazalis *et al.*, [104] investigated that the effects of tetracycline (TC), doxycycline (doxy), and chemically modified tetracycline-3 (CMT-3) on the production of pro-inflammatory mediators and MMPs in an *ex vivo* human whole blood (WB) model stimulated with *Porphyromonas gingivalis* lipopolysaccharide (LPS). Results show that TC, doxy, and CMT-3 can reduce the production of pro-inflammatory mediators (interleukin-1beta (IL-1beta), interleukin-6 (IL-6), interleukin-8 (IL-8), MMP-8, and MMP-9). However, the secretion of IL-1beta and -8 and TNF-alpha by macrophages decreased significantly ($P < 0.05$) when they were pretreated with 2 μM doxycycline, whereas a concentration of 10 μM was required to significantly reduce IL-6 secretion [105]. Pretreatment of macrophages with 10 μM doxycycline prior to *A. actinomycetemcomitans* LPS stimulation resulted in a marked decrease in the phosphorylation of extracellular signal-regulated kinase 1/2 (-76%).

A previous study describes the interaction of α -Lipoic acid (ALA) and dihydrolipoic acid (DHALA) with pro-inflammatory secretory PLA₂ enzymes from inflammatory fluids and snake venoms. *In vitro* enzymatic inhibition of sPLA₂ from *V. russellii*, *N. naja* and partially purified sPLA₂ enzymes from human ascitic fluid (HAF), human pleural fluid (HPF) and normal human serum (HS) by ALA and DHALA was studied [106]. Since in experimental models lipophilic tetracyclines such as minocycline and doxycycline are anti-inflammatory, they examined their effects on PLA₂ activity using two assay systems *in vitro*. They found that minocycline and to a lesser degree doxycycline were markedly inhibitory to both pancreatic and non-pancreatic PLA₂. Using [14C] oleic acid labeled *Escherichia coli* membrane phospholipids as substrate, the IC₅₀ values for minocycline and doxycycline were 3.6×10^{-5} M (18 $\mu\text{g}/\text{ml}$) and 0.98×10^{-4} M (47 $\mu\text{g}/\text{ml}$), respectively [77]. In addition, minocycline has its greatest effect on lipid types, which result from degradation (lipase) reactions, suggesting a lipase inhibition effect and/or direct effect on ocular flora [107]. Currently, patients were randomized to receive 20 mg of subantimicrobial-dose (SD) doxycycline or placebo twice daily for 6 months. Doxycycline treatment significantly reduced the number of inflammatory and non-inflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms [108].

Snake venom PLA₂ inhibitors and therapeutic potential:

Certain molecules like endogenous antitoxic serum proteins with neutralizing capacity against snake venoms have been previously reported [109, 110]. Snake blood-derived inhibitors have been grouped into three major classes (α , β and γ), based on common structural motifs found in other proteins with diverse physiological properties [111-114]. PLA₂ inhibitors (PLIs) from snake blood *Agkistrodon*, *Trimeresurus*, *Bothrops*, *Crotalus*, *Naja*, *Laticaudata* and *Elaphe*. Several reviews dealing with inhibitors of snake venom hemorrhagins [115-120] myotoxins and neurotoxins [121] have been published along the past two decades. Lizano *et al.* [114] reviewed the current knowledge regarding PLA₂s inhibitor proteins derived from both snake and mammalian blood, with particular emphasis on

the classification, molecular and functional characterization of myotoxic PLA₂ inhibitors.

The search for new strategies for treatment of snake envenomations has prompted the discovery of proteins which neutralize the major toxic components of these venoms. These proteins have been isolated from both venomous and non-venomous snakes, mammals, and most recently from medicinal plant extract [114]. Phospholipases A₂s (PLA₂s) are commonly found in snake venoms from Viperidae, Hydrophidae and Elaphidae families have been extensively studied due to their pharmacological and physiopathological effects in living organisms [122]. Several substances have been evaluated regarding their effects against snake venoms and isolated toxins, including plant extracts and compounds from marine animals, mammals and snakes serum plasma, in addition to poly or monoclonal antibodies and several synthetic molecules. The enzyme first attracted the interest of investigators seeking cures for snake-bite, since it is a component of toxic venoms from a number snakes. These venoms produce neurotoxicity, myotoxicity, and inflammation. Interestingly, some non-venomous snakes secrete PLA₂ inhibitors. Venomous snakes produce a natural PLA₂ inhibitor that has also been isolated. Neuroprotective polypeptide (diffusible survival evasion peptide or DSEP) was used to treat rats with traumatic brain injuries. The peptide, which inhibits the enzymatic activity of sPLA₂, blocked the inflammatory response to injury and prevented neural degeneration [123]. Furthermore, the biotechnological potential of PLA₂ inhibitors may provide therapeutic molecular models with antiophidian activity to supplement the conventional serum therapy against these multifunctional enzymes.

a) PLA₂ inhibitors peptides

A basic nonapeptide P2 (antiflammin-2, HDMNKVLDL) which is identical to a portion of the amino acid sequence (residues 246-254) of lipocortin I, has been described to have antiinflammatory activity in a rat paw edema model [124]. P2 (0.05 μM) was also reported to inhibit porcine pancreatic PLA₂. The effect of synthetic P2 (98% pure) on PLA₂ was evaluated in two assay systems. Using porcine pancreatic PLA₂ and phosphatidylcholine/deoxycholate mixed micellar substrate, P2 (0.005-50 μM) had no effect on PLA₂ activity, even in the presence of 2 [125]. Two anti-inflammatory peptides, named antiflammins (AFs), corresponding to a region with high amino acid similarity between lipocortin-1 and uteroglobin were tested for their ability to inhibit transglutaminase (TG) and low-molecular-mass PLA₂. Porcine pancreatic PLA₂ activity and guinea pig hepatic TG activity were determined by arachidonyl release from arachidonyl-phosphatidylcholine and by the incorporation of putrescine into succinylated casein, respectively. AFs inhibited TG activity but did not affect PLA₂ activity. Moreover, porcine pancreatic PLA₂ was activated by TG [126]. This antiflammins showed significant effects on PLA₂ activation by the enzyme called transglutaminase. However, the peptides (antiflammins) failed to show their inhibit effect against purified human synovial fluid PLA₂ (HSF-PLA₂), even at such high concentrations of peptides as 50 μM . *In vivo* anti-inflammatory activity of these peptides was evaluated in several experimental models of inflammation induced by carrageenan, croton-oil [127].

b) Co-crystallization studies PLIs

In 1984, the first venom PLA₂ with a lysine substituting for the highly conserved aspartate 49 was discovered, in the North American crotalid snake *Agkistrodon piscivorus piscivorus* [128]. Ten years later, the first mapping of a 'toxic region' on a Lys-49 PLA₂ was reported, in *B. asper* myotoxin II [129]. After a further decade of research on the Lys-49 PLA₂s, a better understanding of their structural determinants of toxicity and mode of action is rapidly emerging, with myotoxic effector sites identified at the C-terminal region in at least four proteins: *B. asper* myotoxin II, *A. p. piscivorus* (K49 PLA₂), *A. contortrix laticinctus* (ACL myotoxin), and *B. jararacussu* (bothropstoxin I) [130].

A new myotoxic Lys49-PLA₂ isolated from *B. moojeni* snake venom has been crystallized. Suggest a new quaternary structure for this Lys49-PLA₂ in contrast to the dimeric and monomeric structures solved so far for this class of proteins [131,132]. BnSP-7 and BnSP-6, Lys49-PLA₂ isolated from *B. neuwiedi pauloensis* snake venom, were co-crystallized with alpha-tocopherol and X-ray diffraction data were collected for both complexes (2.2 and 2.6 Å). A new "alternative" quaternary conformation for these two complexes compared with all other dimeric Lys49-PLA₂ has been observed [133]. Large single crystals of piratoxin I a Lys49-PLA₂ homologue with low enzymatic activity have been obtained. The crystals belong to the orthorhombic system space group P2 (1)2(1)2(1), and diffract X-rays to a resolution of 2.8 Å. Preliminary analysis reveals the presence of two molecules in the crystallographic asymmetric unit [134]. A myotoxic PLA₂, bothropstoxin II, which exhibits low hydrolytic activity, was crystallized and X-ray diffraction data were collected to a resolution of 2.2 Å. Preliminary analyses reveals the presence of three molecules in the asymmetric unit.

c) Structure based functional studies of PLIs

Several crystal structures of the tetrahedral mimic inhibitors with an sn-2-phosphate, substituent, L-1-(O-octyl-2-(heptyl phosphonyl)-sn-glycero-3-phosphoethanolamine, complexed with secreted PLA₂ from Chinese cobra venom [135, 136], PLA₂ and peptide inhibitor from *Russells viper* venom [137], bee venom [138, 139], and inflammatory exudates [140, 141] have been reported. Also the crystal structure of a sn-2-acyl-amino analogue of phospholipids complexed with the engineered (without the residues of the surface 62-66) porcine PLA₂ [142, 143] has been determined. The crystal structures of the complexes of bovine pancreatic PLA₂ with an inhibitor n-dodecyl-phosphorylcholine [144-147] and human synovial PLA₂ with an acyl amino analogue of phospholipids [148] are also of some interest. Recently, a series of indole inhibitors of human secretory PLA₂ were developed [149-151].

Despite differences in their primary sequences (~30% homology only), crystal structures of PLA₂ from bovine pancreas (type I) and human synovial fluid (type II) are almost superimposable and, not surprisingly, the active sites from both types of enzymes are virtually identical [152]. Asp-99 and His-48 form an essential catalytic dyad in the fashion of serine proteases [153]. Tyr-52 and Tyr-73 appear to be associated with these two residues via a hydrogen bonding network, but there is evidence [154] that Tyr-52 is not essential for the catalytic reaction. From structure-function studies of type I and II enzymes, the first eight residues at the NH2 terminus together with Tyr-69, based

on the numbering system of Renetseder *et al*, [155], are thought to play a functional role in interfacial binding of the enzyme to aggregated substrate [156]. Both chemical modification [157] and site-directed mutagenesis [158-160] studies have shown that the NH2-terminal residue is crucial for activity on micellar substrates. Further studies with type I PLA₂ [160, 161] have shown that significant alterations of the invariant hydrophobic face of the NH2-terminal amphipathic helix (residues 2, 5, or 9) are detrimental to enzyme activity. Residue 10 is necessary for interfacial binding, and changes in other residues have a modest or no effect on catalytic activity. Production of the fully active enzyme depends on conformational changes of the NH2-terminal helical region that occur firstly on interfacial binding to the phospholipid micelle and secondly on substrate binding at the active site [162].

Nuclear magnetic resonance (NMR) spectroscopic studies of porcine pancreatic PLA₂ indicated that the first few residues of the NH2 terminus are not alpha-helical in solution but become helical and rigid on formation of a ternary complex with micelles or a substrate analogue [163-165]. X-ray crystallographic studies showed that the NH2-terminal and β-loop regions (residues 62-73) are held by hydrogen bonding in the active enzyme conformation and form the catalytic network involving His-48, Tyr-52, Tyr-73, and Asp-99 [166-169]. Recent studies have shown that there is a strong but non-covalent association between residues of the NH2-terminal amphipathic helix and the β-loop region, suggesting that a novel approach to enzyme inhibition may be to provide one or another of these domains as free peptide. Peptides from the β-loop region, corresponding to residues 70-74 in three different type II PLA₂ molecules, were made and added to mixed micelle assays for the PLA₂. Significant enzyme inhibition occurred for each of the three peptides, and inhibition was specific to the PLA₂ from which the peptide was derived.

Mechanism action of PLA₂ inhibitors:




Figure 2: Flow chart represents the simple mechanism of action of inhibitors on interleukin (IL) induced expression of secretory phospholipase A₂ (sPLA₂) and matrix metalloproteinase. Cytokines induced the expression of sPLA₂-IIA and MMP via activation of mitogen-activated protein kinase (MAPK) etc.

Natural inhibitor inhibits p38 MAPK phosphorylation and slows down the activation of transcription factor which control the transcription of sPLA₂, MMPs and inflammatory cytokines. MAPKK -kinase, sPLA₂-IIA-secretory phospholipase A₂ Group IIA, PGE₂-prostaglandin E₂.

Secretory phospholipase A₂ (sPLA₂-IIA) is an inflammatory protein known to play a role in the pathogenesis of envenomation. Over the last 30 years, interest in PLA₂ has grown beyond its enzymatic capacity to cleave phospholipids. PLA₂ cleave membrane phospholipids to release arachidonic acid, the precursor to a large family of pro-inflammatory eicosanoids including prostaglandins and leukotrienes. Current therapies include non-steroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenases (COX-1, COX-2) but have no effect on the production of leukotrienes or platelet activating factor (PAF) [170, 171]. In addition, existing treatment with non-steroidal drugs is the only choice for the treatment of anti-inflammatory. However, the available treatments (such as targeting tumour necrosis factor and TNF signaling) do not cure the disease in the clinical settings, and ultimately leads to adverse side effects [172]. A simple mechanism of action of inhibitors on interleukin (IL) induced expression of sPLA₂ and matrix metalloproteinase proposed. Cytokines induced the expression of sPLA₂-IIA and MMP via activation of mitogen-activated protein kinase (MAPK) etc. Natural inhibitor inhibits p38 MAPK phosphorylation and slows down the activation of transcription factor which control the transcription of sPLA₂, matrix metalloproteinase (MMP) such as MMP-1, MMP-2, MMP-3 and MMP-9 and inflammatory cytokine like IL-1, IL-6 and TNF -alpha etc. The effects of inhibitors inhibit the sPLA₂ action and decrease the formation of arachidonic acid for prostaglandin production (Figure 2).

Conclusions and future impacts:

Snakebite envenomations and their severity remain is not clear yet. However, this poorly neutralized by conventional antivenom serotherapy. In severe cases, these local effects may lead to permanent tissue loss, disability or amputation. A renewed interest in the phenomenon of inter- and intra-species resistance towards the toxicity of snake venoms, coupled with the search for new strategies for treatment of snake envenomations, has prompted the discovery of proteins which neutralize the major toxic components of these venoms. Naturally available inhibitors occupy an important place in the potential to neutralize the toxic effects caused by snake venom proteins. It has been well recognized for several years that animal sera, some plant and marine extracts, antibiotics from synthetic chemicals are the most potent in neutralizing snake venoms. The implications of these new groups of PLA₂ toxin inhibitors in the context of our current understanding of snake biology as well as in the development of novel therapeutic reagents in the treatment of snake envenomations world-wide are discussed. Furthermore, the biotechnological potential of PLA₂ inhibitors may provide therapeutic molecular models with antiophidian activity to supplement the conventional serum therapy against these multifunctional enzymes. In addition to that the clinically importance of these natural inhibitors may lead to the development of new novel antivenoms therapeutics for the efficient treatment of the envenomation.

Acknowledgments:

The authors are grateful to the National University of Singapore for the financial support (Grant No: R-181-000 078 122) provided under the ARF.

References: (Please provide PMID)

- [1] Pithayanukul P et al. *J. Ethnopharmacol.* 2004 **90**: 347
- [2] Viravan C et al. *Trans R Soc Trop Med Hyg.* 1992 **86**: 100
- [3] Gutiérrez JM & Lomonte B. *Toxicon* 1995 **33**:1405
- [4] Ownby CL, *J. Toxicol Toxins Rev.* 1998 **17**: 213
- [5] Teixeira C et al. *Toxicon.* 2009 **4**: 67
- [6] Yu BZ et al. *Biochemistry.* 1998 **37**: 12576
- [7] Balsinde J, *J Biol Chem.* 1999 **274**: 25967
- [8] Lambeau G & Lazdunski M, *Trends Pharmacol Sci.* 1999 **20**: 162
- [9] Six DA & Dennis EA, *Biochim Biophys Acta.* 2000 **1488**: 1
- [10] Ownby CL et al. *Toxicon* 1999 **37**: 411
- [11] Gutiérrez JM et al. *Toxicon.* 1984 **22**: 115
- [12] Soares AM et al. *Toxicon.* 1998 **36**: 503
- [13] Angulo Y et al. *Toxicon.* 2005 **46**: 291
- [14] Andrião-Escarso S H, *Biochimie.* 2000 **82**: 755
- [15] Faria de L. *Toxicon.* 2001 **39**: 825
- [16] Xu S, *Acta Cryst.* 2002 **58**: 1836
- [17] Ramasamy R et al. *Clinical and Experimental Pharmacology and Physiology* 2005 **32**: 7
- [18] Wang Y. *Toxicon.* 2008 **51**: 1131
- [19] Fernández J. *Biochime.* 2010 **92**: 273
- [20] Teixeira CFP et al. *Toxicon.* 2003 **42**: 947
- [21] Iansante V et al. *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry.* 2009 **8**: 51
- [22] Brogden KA. *Nature Reviews Microbiology.* 2005 **3**: 238
- [23] Schwarz WH & Zverlov VV, *Mol Microbiol.* 2006 **60**: 1323
- [24] Thwin MM et al. *J Med Chem.* 2007 **50**: 5938
- [25] Silvana M et al. *Current Topics in Medicinal Chemistry.* 2007 **7**: 743.
- [26] Arce-Estrada V. *Vaccine.* 2009 **27**: 460.
- [27] Soares AM et al. *Current Medicinal Chemistry.* 2005 **12**: 2625.
- [28] Chandrashekhara KT et al. *Phytother Res.* 2009 **23**: 1082
- [29] Harsha VH et al. *Fitoterapia.* 2002 **73**: 281
- [30] Harsha VH et al. *J. Ethnopharmacol.* 2003 **84**: 37
- [31] Parinitha M et al. *J Ethnopharmacol.* 2005 **98**: 307
- [32] Ticli FK et al. *Toxicon.* 2005 **46**: 318
- [33] Perumal Samy R et al. *J Ethnopharmacol.* 2008 **115**: 302
- [34] Mukherjee AK et al. *Toxicon.* 2008 **51**: 1548
- [35] Lizano S et al. *Toxicon.* 2003 **42**: 963
- [36] Chatterjee I et al. *Indian J Experimental Biol.* 2004 **42**: 468
- [37] Shirwaikar A et al. *J Ethnopharmacol.* 2004 **94**: 267
- [38] Grish H et al. *Fitoterapia.* 2004 **75**: 378
- [39] Torres AM et al. *Nat Prod Coummun.* 2011 **6**: 1393
- [40] Pithayanukul P et al. *Phytother Res.* 2010 **24**: S56
- [41] Alam MI et al. *Toxicon.* 1994 **32**: 1551
- [42] Alam MI & Gomes A, *Toxicon.* 1998 **b36**: 207
- [43] Pereira PN et al. *Planta Medica.* 1994 **60**: 99
- [44] Otero R et al. *J Ethnopharmacol.* 2000a **73**: 233
- [45] Otero R et al. *J Ethnopharmacol.* 2000b **71**: 505
- [46] Miyake A et al. *J Pharmacol Exp Ther.* 1992 **263**: 130
- [47] Mors WB et al. *Toxicon.* 1989 **27**: 1003
- [48] Mors WB et al. *Phytochemistry.* 2000 **55**: 627
- [49] Domont GB et al. *Toxicon* 1991 **29**: 1183
- [50] Borges MH et al. *J Ethnopharmacol.* 2005 **98**: 21
- [51] Moreno JJ, *Immunopharmacology.* 1993 **26**: 1
- [52] Lindahl M & Tagesson C, *Inflammation.* 1997 **21**: 347

- [53] Alcaraz MJ & Hoult JRS, *International Pharmacodynamics* 1985 **278**: 4
- [54] Grau A & Ortiz A, *Chem Phys Lipids*. 1998 **91**: 109
- [55] Bazan NG *et al.* *J Neurotrauma*. 1995 **12**: 791
- [56] Jackson JR *et al.* *Biochim Biophys Acta*. 1998 **1392**: 145
- [57] Kohler C *et al.* *Inflammation*. 1993 **17**: 245
- [58] Potts BC *et al.* *J Natural Products*. 1992 **55**: 1701
- [59] Glaser KB & Jacobs RS, *Biochem Pharmacol*. 1986 **35**: 449
- [60] Glaser KB *et al.* *Biochem. Pharmacol*. 1988 **37**: 3639
- [61] Jacobson PB *et al.* *Biochemical Pharmacol*. 1990 **39**: 1557
- [62] Scoriente A *et al.* *Curr Med. Chem*. 1999 **6**: 415
- [63] Monti MC *et al.* *Chembiochem*. 2007 **8**: 1585
- [64] Carvalho de MS & Jacobs RS, *Biochem Pharmacol*. 1991 **42**: 1621
- [65] Dal Piaz F *et al.* *Chembiochem*. 2002 **29**: 687
- [66] Wiemer DE, *Experientia*. 1991 **47**: 851
- [67] Yoo H *et al.* *J Nat Prod*. 2002 **65**: 51
- [68] Shoeib NA *et al.* *J. Nat. Prod*. 2004 **67**: 1445
- [69] Narendra Sharath Chandra JN *et al.* *Curr Top Med Chem*. 2007 **7**: 787
- [70] Nirmal N *et al.* *Indian J Biochem Biophys*. 2008 **45**: 256
- [71] ElAttar TM *et al.* *J Periodontal Res*. 1988 **23**: 285
- [72] Pruzanski W *et al.* *Biochem Pharmacol*. 1992 **44**: 1165
- [73] Van Barr HM *et al.* (*Letter*) *Br J Dermatol*. 1987 **117**: 131
- [74] Amin AR *et al.* *Proc Natl Acad Sci. USA*. 1996 **93**: 14014
- [75] Golub LM *et al.* *J Periodontal Res*. 1984 **19**: 651
- [76] Smith RL *et al.* *J Bone Joint Surg [Am]* 1987 **69**: 1063
- [77] Pruzanski W *et al.* *J. Rheumatol*. 1998 **25**: 1807
- [78] Golub LM *et al.* *Crit Rev Oral Biol Med*. 1991 **2**: 297
- [79] Golub LM *et al.* *Curr Opin Dent*. 1992 **2**: 80
- [80] Steinsvoll S, *Microbial Ecology in Health and Disease*. 2004 **16**: 1
- [81] Islam MM *et al.* *American J Pathol*. 2003 **163**: 1557
- [82] Ryan ME *et al.* *Curr Med Chem*. 2001 **8**: 305
- [83] Fisher JF & Mobashery S, *Cancer and Metastasis Reviews*. 2006 **25**: 115
- [84] Sugatani J *et al.* *J Antibiot (Tokyo)*. 1979 **32**: 734
- [85] Rucavado A *et al.* *Toxicon*. 2008 **52**: 754
- [86] Meng Q *et al.* *Clin Exp Metastasis*. 2000 **18**: 139
- [87] Seftor RE *et al.* *Clin Exp Metastasis*. 1998 **16**: 217
- [88] Uitto VJ *et al.* *Ann NY Acad Sci*. 1994 **6**: 140
- [89] Golub LM *et al.* *J. Den. Res*. 1987 **66**: 1310
- [90] Ingman T *et al.* *J Periodontol*. 1993 **64**: 82
- [91] Sandler C *et al.* *Inflammation Res*. 2005 **54**: 304
- [92] Lee HM *et al.* *Curr Med Chem*. 2001 **8**: 257
- [93] Sorsa T *et al.* *J Rheumatol*. 1998 **25**: 975
- [94] Amin AR *et al.* *FEBS Lett*. 1997 **410**: 259
- [95] Tilley BC *et al.* *Ann Intern Med*. 1995 **122**: 81
- [96] Nip LH *et al.* *J Periodontal Res*. 1993 **28**: 379
- [97] Greenwald RA *et al.* *J Rheumatol*. 1987 **14**: 28
- [98] Paulus HE, *Annals of Internal Medicine*. 1995 **122**: 147
- [99] Vadas P *et al.* *Am J Pathol*. 1989 **134**: 807
- [100] Kloppenburg M *et al.* *Br J Rheumatol*. 1992 **31**: S41
- [101] Agostino PD *et al.* *International J Immunopharmacol*. 2001 **1**: 1765
- [102] Webster G & Del Rosso JQ, *Dermatologic Clinics*. 2007 **25**: 133
- [103] Bastos LFS *et al.* *British J Pharmacol*. 2009 **55**: 714
- [104] Cazalis J, *Inflammation*. 2009 **32**: 130
- [105] Cazalis J, *J Periodontol*. 2008 **79**: 1762
- [106] Jameel NM *et al.* *Life Sciences*. 2006 **80**: 146
- [107] Shine WE *et al.* *Experimental Eye Research*. 2003 **76**: 417
- [108] Skidmore R *et al.* *Arch Dermatol*. 2003 **139**: 459
- [109] Thwin MM & Gopalakrishnakone P, *Toxicon*. 1998 **36**: 147
- [110] Thwin MM *et al.* *Biochemistry*. 2000 **39**: 9604
- [111] Behrendt N *et al.* *J Biol Chem*. 1991 **266**: 7842
- [112] Ohkura N *et al.* *J Biochem*. 1993 **113**: 413
- [113] Okumura K *et al.* *J Biol Chem*. 1998 **273**: 19469
- [114] Lizano S *et al.* *Biochem J*. 2000 **346**: 631
- [115] Okumura K *et al.* *IUBMB Life*. 1999 **48**: 99
- [116] Jeyaseelan K *et al.* *Mol Biol Evol*. 2000 **17**: 1010
- [117] Fortes-Dias CL *et al.* *Toxicon*. 2003 **41**: 909
- [118] Okumura K *et al.* *IUBMB Life*. 2003 **55**: 539
- [119] Steve Quirós S *et al.* *Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology*. 2006 **46**: 60
- [120] Oliveira CZ *et al.* *Biochimie*. 2008 **90**: 1506
- [121] Fuly AL *et al.* *Toxicon*. 2000 **38**: 961
- [122] Marcussi S *et al.* *Curr Top Med Chem*. 2007 **7**: 743
- [123] Cunningham TJ *et al.* *J Neurotrauma*. 2004 **21**: 1683
- [124] Miele L *et al.* *Nature*. 1988 **335**: 726
- [125] Hope WC *et al.* *Agents Actions*. 1991 **34**: 77
- [126] Moreno JJ. In *Immunopharmacol*. 2006 **6**: 300
- [127] Cabré F *et al.* *Biochem Pharmacol*. 1992 **44**: 519
- [128] Maraganore JM *et al.* *J Biol Chem*. 1984 **259**: 13839
- [129] Lomonte B *et al.* *J Biol Chem*. 1994 **269**: 29867
- [130] Lomonte B *et al.* *Toxicon*. 2003 **42**: 885
- [131] Marchi-Salvador DP. *Acta Crystallogr Sect F Struct Biol Cryst Commun*. 2006 **62**: 600
- [132] Marchi-Salvador DP *et al.* *Acta Crystallogr Sect F Struct Biol Cryst Commun*. 2005 **61**: 882-4
- [133] Santos dos JI *et al.* *Protein Pept Lett*. 2005 **2**: 819
- [134] Canduri F *et al.* *Toxicon*. 1998 **36**: 547
- [135] White SP *et al.* *Science*. 1990 **250**: 1560
- [136] Pan YH *et al.* *J Biol Chem*. 2002 **277**: 29086
- [137] Chandra V *et al.* *J Biol Chem*. 2002 **277**: 41079
- [138] Scott DL *et al.* *Science*. 1990 **250**: 1563
- [139] Fenard D *et al.* *Molecular Pharmacol*. 2001 **60**: 341
- [140] Scott DL *et al.* *Science*. 1991 **254**: 1007
- [141] Sedgwick AD *et al.* *Inflammation*. 2005 **6**: 13
- [142] Thunnissen MMGM *et al.* *Nature*. 1990 **347**: 689
- [143] Burke JE & Dennis EA, *J Lipid Res*. 2009 **50**: S237
- [144] Tomoo K *et al.* *Proteins: Struct Funct Genet*. 1994 **19**: 330
- [145] Sekar K *et al.* *Biochemistry* 36. 1997 **46**: 14186
- [146] Sekar K, *Curr Top Med Chem*. 2007 **7**: 779
- [147] Singh N *et al.* *Curr Top Med Chem*. 2007 **7**: 757
- [148] Cha SS *et al.* *J Med Chem*. 1996 **39**: 3878
- [149] Schevitz RW *et al.* *Nat Struct. Biol*. 1995 **2**: 458
- [150] Scott Sawyer J *et al.* *J Med Chem*. 2005 **48**: 893
- [151] Zhou L *et al.* *Nature*. 1991 **352**: 79
- [152] Wery JP *et al.* *Nature*. 1991 **352**: 79
- [153] Dijkstra BW *et al.* *Nature*. 1981 **289**: 604
- [154] Dupureur C *et al.* *Biochemistry*. 1992 **31**: 6402
- [155] Renetseder R *et al.* *J Biol Chem*. 1985 **260**: 11627
- [156] Randolph A *et al.* *Toxicon*. 1998 **26**: 721
- [157] Yang C C. John Wiley & Sons, UK, p. 185, 1997
- [158] Di Marco S *et al.* *J Biochem*. 1992 **112**: 350
- [159] Marki F & Hanulak V, *J Biochem*. 1993 **113**: 734
- [160] Maliwal B *et al.* *Biochemistry*. 1994 **33**: 4509
- [161] Liu X *et al.* *Biochemistry*. 1995 **34**: 7322
- [162] Kilby PM *et al.* *Biochem J*. 1995 **305**: 935
- [163] Dekker N *et al.* *Eur J Biochem*. 1991 **199**: 601
- [164] Peters A *et al.* *Biochemistry*. 1992 **31**: 10024
- [165] van den Berg B *et al.* *Struct Biol*. 1995 **2**: 402

- [166] Dijkstra B *et al.* *J Mol Biol.* 1981 **147**: 97
[167] Scott DL *et al.* *Science.* 1990 **250**: 1541
[168] Brunie S *et al.* *J Biol Chem.* 1985 **260**: 9742
[169] Dijkstra BW *et al.* *J Mol Biol.* 1982 **147**: 97
[170] Miele L, *Curr Med Chem.* 2005 **12**: 3011
- [171] Zhang Z *et al.* *Mol Pharmacol.* 2011 Dec 5 [Epub ahead of print]
[172] Smolen JS & Steiner G, *Nat Rev Drug Discov.* 2003 **2**: 473488

Edited by P Kanguane

Citation: Samy *et al.* *Bioinformation* 8(1): 048-057 (2012)

License statement: This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original author and source are credited.